(Q45233558)

English

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

scientific article published on 11 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers (English)

1 reference

Europe PubMed Central

11 December 2017

Mycobacterium tuberculosis

0 references

object named as

Peter Andersen

13

0 references

Tom H M Ottenhoff

10

object named as

Tom H M Ottenhoff

1 reference

Europe PubMed Central

11 December 2017

3

object named as

Corine Prins

1 reference

Europe PubMed Central

11 December 2017

author name string

Jaap T van Dissel

1

1 reference

Europe PubMed Central

11 December 2017

Sandra M Arend

2

1 reference

Europe PubMed Central

11 December 2017

Peter Bang

4

1 reference

Europe PubMed Central

11 December 2017

Pernille Nyholm Tingskov

5

1 reference

Europe PubMed Central

11 December 2017

Karen Lingnau

6

1 reference

Europe PubMed Central

11 December 2017

Jan Nouta

7

1 reference

Europe PubMed Central

11 December 2017

Michèl R Klein

8

1 reference

Europe PubMed Central

11 December 2017

Ida Rosenkrands

9

1 reference

Europe PubMed Central

11 December 2017

Ingrid Kromann

11

1 reference

Europe PubMed Central

11 December 2017

T Mark Doherty

12

1 reference

Europe PubMed Central

11 December 2017

language of work or name

0 references

publication date

11 March 2010

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

28

1 reference

Europe PubMed Central

11 December 2017

20

1 reference

Europe PubMed Central

11 December 2017

3571-3581

1 reference

Europe PubMed Central

11 December 2017

Planning to improve global health: the next decade of tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Advances in tuberculosis vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Tuberculosis subunit vaccines: from basic science to clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Envisioning future strategies for vaccination against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Developing an improved vaccine against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Mycobacterium tuberculosis and the environment within the phagosome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Tuberculosis subunit vaccine development: on the role of interferon-γ

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Vaccine adjuvants: current state and future trends

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Effects of physical activity on creatine phosphokinase and the isoenzyme creatine kinase-MB.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

TB subunit vaccines--putting the pieces together

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

TB vaccines: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

The success and failure of BCG - implications for a novel tuberculosis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Persistence of the immune response induced by BCG vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Progress in tuberculosis vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Vaccines against intracellular infections requiring cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.094

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.02.094

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45233558&oldid=2142981858"